Cara Therapeutics, Inc.

Cara Therapeutics develops therapeutics for chronic pruritus treatment in the US. Its lead product is KORSUVA injection for moderate-to-severe pruritus associated with CKD in adults undergoing hemodialysis. Oral difelikefalin is in Phase II/III trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi, Vifor Fresenius Medical Care Renal Pharma, and Chong Kun Dang Pharmaceutical Corporation for development and commercialization of drug products containing difelikefalin.

Overview

Sector

Biotechnology

Target Price

- USD

Current Price

5.3 USD

Potential

Strengths

Price to book ratio (0.30) is lower than the sector mean (23.22)

Weaknesses

With a depreciation Potential of -100.00% , based on our advanced cash flow analysis, it suggests the stock may be overvalued
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (-145.76%) is significantly lower than the sector mean (-46.31%)
EV/EBITDA (100.00) is significantly higher than the sector mean (-2.03)
EV/EBIT (100.00) is significantly higher than the sector mean (54.49)
EBITDA Margin (0.00%) appears relatively low

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	0.3
Price/Free Cash Flow'	100.0
ROIC	100.0%
Net Debt/EBITDA	0.8